RELATIONAL DRUG DESIGN ™
To Empower the Body
To Prevent, Treat and Resist Diseases
While our team has a breadth of experience – drug development, clinical, regulatory affairs and commercialization of products – the singular element that drives the team is a sense of fierce urgency to develop and deliver therapeutics to patients who are not served by the currently available options.
Parag G. Mehta, PhD, Co-founder and CEO is a serial entrepreneur with a track record of commercializing novel chemistry based innovations. He has strong background in biotechnology, organic, macromolecular and biochemistry and material science. His experience encompasses product R&D, global business development, manufacturing and capitalization of companies through public and private financing. He received his PhD in Chemistry from Rensselaer Polytechnic Institute, Troy, NY and MSc in Chemistry from Indian Institute of Technology, Mumbai, India.
Bharat Aggarwal, PhD, Scientific Advisor, Director of Inflammation Research Institute in San Diego, CA and a just retired Chaired professor and chief of the Cytokine Research at M.D. Anderson Cancer Center, Univ. of Texas is world’s foremost researcher in areas of inflammation and is well-known for his ground-breaking work on use of natural products to combat many diseases. Earlier at Genentech his team characterized TNF-alpha and TNF-beta, key cytokines involved in cancer. He has made seminal contributions in inflammation biology, role of cytokines in tumor cell growth and mechanism of tumor cell resistance. He has authored more than 500 original articles in peer-reviewed journals, edited 12 books, is co-inventor of 33 patents, and has Scholar h-index of 157 with 89,500 citations.
David C. Christiani, MD. MPH, MS, Scientific Advisor is a Professor of Medicine at Harvard Medical School, Physician, Pulmonary and Critical Care Unit of MGH, and the Elkan Blout Professor of Environmental Genetics at the Harvard School of Public Health. He has conducted clinical trials in lung disease, and has chaired or served on several DSMB’s for ongoing trials in lung disease and cancer. He has been a leader in studying biomarkers of risk and outcome in cancer and in acute and chronic lung injury. He has authored or co-authored over 600 publications. In 2012, he was appointed by President Obama to serve on the National Cancer Advisory Board.